Novavax new crown trimeric protein vaccine is comparable to mRNA vaccine, clover biology is on the way

On June 14, 2021, Novavax announced that the new crown vaccine NVX-CoV2373 Phase III clinical success, with an overall protection rate of 90.
4% and a critical illness protection rate of 100%
.

NVX-CoV2373 is a trimeric full-length S protein vaccine, using Matrix-M adjuvant
.

Clover Biology’s SCB-2019 is also a trimeric S protein vaccine, constructed on the basis of its Trimer-Tag technology, and is currently in the phase III clinical stage
.

In the first phase of clinical trials, Clover Biology used GlaxoSmithKline’s AS03 adjuvant and Dynavax’s CpG1018 plus aluminum adjuvant, respectively.
Due to the stronger side effects of AS03 adjuvant, Clover used CpG1018 plus aluminum adjuvant in the third phase of clinical trials
.

AS03 adjuvant and CpG1018 are two of the six adjuvants used in all marketed vaccines.
The mechanism of action is shown in the figure below
.

       to sum up

       In the new crown epidemic, the mRNA vaccine has been crushed with an overwhelming protection rate advantage.
Novavax's trimeric protein vaccine is the first protein vaccine with a protection rate comparable to that of the mRNA vaccine
.